In this scenario, deregulation of the cell cycle represented one of the most interesting therapeutical targets, since dysregulation of the cyclin D-CDK4/6-pRb pathway is frequent in hormonal receptor (HR) positive BC and represents a key mediator of endocrine resistance [3,4,5,6,7,8,9]. This evidence concerns the gene CDK4 and breast cancer.